Dr. Richardson - Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma
Paul Richardson, MD Jerome Lipper Myeloma Center Dana Farber Cancer Institute Boston, MA Member, IMF Board of Scientific Advisors
back
print
related articles
Be the first to comment